News
CHMP recommends Ozawade for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.- Bioproject Pharma
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozawade (pitolisant), intended for the treatment of excessive daytime sleepiness in obstructive sleep apnoea.
The applicant for this medicinal product is Bioproject Pharma. The benefits of Ozawade are its ability to improve wakefulness in patients with obstructive sleep apnoea. The most common side effects are headache and insomnia..
Condition: Sleeping Disorders
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.